Not provided
Not provided
Not provided
Not provided
Not provided
Pandemic impacted ability to recruit and enroll
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study addresses a difficult barrier to hepatitis C elimination, specifically development and maintenance of a productive relationship between the health care provider and patient to ensure both treatment success and engagement in harm reduction services. Improvements in these domains may be observed through the use of a technique called "Motivational Interviewing" (MI). The aim of this study is to determine whether a customized motivational interviewing curriculum by general primary care and addictions medicine primary care providers changes rates of curative hepatitis C therapy completion.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Motivational Interviewing Training | Active Comparator | Health care providers will be trained in motivational interviewing for use in Hepatitis C patient encounters. |
|
| Standard Clinical Encounter | No Intervention | Health care providers will not be trained in motivational interviewing for use in Hepatitis C patient encounters. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Motivational Interviewing Training | Behavioral | Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions. A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers. |
| Measure | Description | Time Frame |
|---|---|---|
| HCV Treatment Completion | To measure the number of patients who complete HCV therapy | Through study completion, an average of 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Time from care engagement to treatment initiation | Through study completion, an average of 2 years | |
| Number of unique Hepatitis C related and unrelated health system visits | Through study completion, an average of 2 years |
Not provided
Patient Inclusion Criteria:
Patient Exclusion Criteria:
Health Care Provider Inclusion Criteria:
Health Care Provider Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nova Scotia Health Authority | Halifax | Nova Scotia | B3H 1V7 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006526 | Hepatitis C |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Number of scheduled and attended medical care appointments | Through study completion, an average of 2 years |
| Self-reported intent to initiate and maintain HCV treatment assessed by questionnaire | Through study completion, an average of 2 years |
| Healthcare provider knowledge, attitudes, and behavior about motivational interviewing and training assessed by questionnaire | Through study completion, an average of 2 years |
| Time to complete prescribed HCV treatment course | Through study completion, an average of 2 years |
| Percentage of eligible individuals that initiate HCV therapy | Through study completion, an average of 2 years |
| D014777 |
| Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |